

Conflict of interest register: Clinical Practice Guidelines for the Diagnosis and Management of Melanoma – Extract of document

**Professor John Thompson**

Executive Director, Melanoma Institute Australia

Consultancy fees/ honorarium Honoraria received from **GlaxoSmithKline, Bristol Myers Squibb, Provectus and Merck Sharp Dohme**

Support for travel or accommodation Travel support received from **GlaxoSmithKline, Bristol Myers Squibb and Provectus**

**Professor Georgina Long**

Medical oncologist, Melanoma Institute Australia; Professor of Melanoma Medical Oncology and Translational Research (MIA, University of Sydney, Mater and Royal North Shore Hospitals), NSW

Consultancy fees/ honorarium **BMS, Novartis, Roche, Amgen, Pierre Fabre, MERCK and Array** Support for travel or accommodation **BMS, Novartis, Roche, Amgen, Pierre Fabre, MERCK and Array** Other (e.g. registration fees for conferences, institutional interests, etc – see policy) **BMS, Novartis, Roche, Amgen, Pierre Fabre, MERCK and Array**

**Dr Matteo Carlino**

Medical Oncologist Westmead and Blacktown Hospitals, Melanoma institute Australia Clinical Senior lecturer University of Sydney

Consultancy fees/honorarium: **Board member Bristol Myers Squibb, MSD, Novartis**

Travel support and registration fees from Bristol Myers Squibb & MSD

**Professor Richard Kefford AM**

Professor of Cancer Medicine, Macquarie University

Support for travel or accommodation Support for conference attendance; **Bristol Myers Squibb, Merck**

Registration fees for conferences **Bristol Myers Squibb, Merck**

**A/Prof Alexander Menzies**

Medical Oncologist, CINSW Senior Research Fellow, Melanoma Institute Australia, Royal North Shore Hospital, The University of Sydney

Consultancy fees/honorarium **Bristol Myers Squibb, MSD, Novartis, Roche, Pierre Fabre**

Support for travel or accommodation ASCO 2017 **Bristol Myers Squibb**